We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VEEV Expands IQVIA Partnership With Clinical Operations Software Suite
Read MoreHide Full Article
Key Takeaways
VEEV expands its IQV partnership, adding clinical operations applications as enterprise standards for studies.
Veeva's CTMS, eTMF, Study Startup and Site Connect tools aim to improve trial efficiency.
VEEV's expanded collaboration could drive broader adoption and cross-selling.
Veeva Systems (VEEV - Free Report) recently expanded its partnership with IQVIA (IQV - Free Report) , with the latter selecting additional Veeva clinical operations applications as enterprise standard solutions across its clinical development studies. The agreement builds on the companies’ previously announced electronic data capture (EDC) partnership and strengthens their collaboration in clinical research.
The expanded partnership is an encouraging development for Veeva, as IQVIA’s selection of its clinical operations applications as enterprise standards strengthens the company’s presence in clinical research technology.
Veeva has also continued to expand its customer relationships, with recent partnerships involving Servier and Amgen underscoring demand for its cloud-based solutions across the life sciences industry.
These developments could support broader adoption of Veeva’s clinical applications and strengthen its competitive position over the long term. However, the IQVIA agreement's contribution to revenue growth and profitability will depend on implementation timelines and subsequent customer demand.
Likely Trend of VEEV Stock Following the News
Following the announcement, shares of VEEV traded flat in yesterday’s trading. Year to date, shares of the company have gained 35.1% compared with the industry’s 19.1% growth. However, the S&P 500 has risen 13.8% in the same timeframe.
The expanded partnership with IQVIA is likely to support VEEV’s long-term growth by strengthening the adoption of its clinical applications across a major clinical research organization. Making Veeva’s solutions standard applications for IQVIA’s clinical development studies could increase product visibility, deepen its presence in the clinical research ecosystem and create opportunities to reach more biopharmaceutical customers. The collaboration also strengthens the value proposition of Veeva’s clinical technology portfolio by enabling deeper integration and more efficient workflows.
VEEV currently has a market capitalization of $47.9 billion.
Image Source: Zacks Investment Research
More on Veeva’s Clinical Operations Software Suite
VEEV is expanding its role in clinical research by being selected as the enterprise-standard solution for IQVIA’s clinical development studies. The agreement covers Veeva Clinical Trial Management System (CTMS), electronic Trial Master File (eTMF), Study Startup and Site Connect, extending the companies’ previously announced EDC partnership. These applications are designed to support key stages of clinical trials, from study planning and site activation to trial management and documentation.
Their adoption across IQVIA’s clinical development activities is expected to support more connected workflows, improve operational efficiency and strengthen coordination among clinical research stakeholders. The collaboration also builds on the companies’ complementary capabilities, with IQVIA emphasizing that customers will retain flexibility in selecting electronic data capture, randomization and trial supply management and electronic clinical outcome assessment technologies.
Expanded Collaboration Could Strengthen Veeva’s Market Position
The partnership could provide Veeva with a broader channel to market its clinical applications to biopharmaceutical companies that rely on IQVIA for clinical research services. IQVIA’s selection of multiple Veeva applications as enterprise standards may also strengthen customer confidence in the company’s technology and encourage sponsors to consider adopting a wider range of its solutions.
In addition, IQVIA will make Veeva’s full clinical solution portfolio available to sponsors seeking an integrated technology stack, creating a potential avenue for cross-selling. The collaboration is aimed at improving trial efficiency, strengthening clinical site engagement and enabling better-informed decisions through more connected technology workflows.
Over the longer term, these factors could support broader product adoption and recurring revenue growth for Veeva.
However, the companies have not disclosed financial terms or a deployment timeline, making the eventual revenue contribution difficult to quantify at this stage.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
VEEV continues to strengthen its position in the life sciences software market as the Veeva DQS platform expands reach across clinical trials. The company said the solution now supports data cleaning across more than 1,000 studies involving over 1 million subjects, highlighting growing adoption of its clinical data management capabilities.
The expanding scale of Veeva DQS is encouraging as biopharma companies increasingly prioritize efficient data management amid rising clinical trial complexity.
VEEV’s Zacks Rank & Key Picks
Currently, VEEV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Merit Medical Systems, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.
View the Zacks #1 Rank List
Image: Bigstock
VEEV Expands IQVIA Partnership With Clinical Operations Software Suite
Key Takeaways
Veeva Systems (VEEV - Free Report) recently expanded its partnership with IQVIA (IQV - Free Report) , with the latter selecting additional Veeva clinical operations applications as enterprise standard solutions across its clinical development studies. The agreement builds on the companies’ previously announced electronic data capture (EDC) partnership and strengthens their collaboration in clinical research.
The expanded partnership is an encouraging development for Veeva, as IQVIA’s selection of its clinical operations applications as enterprise standards strengthens the company’s presence in clinical research technology.
Veeva has also continued to expand its customer relationships, with recent partnerships involving Servier and Amgen underscoring demand for its cloud-based solutions across the life sciences industry.
These developments could support broader adoption of Veeva’s clinical applications and strengthen its competitive position over the long term. However, the IQVIA agreement's contribution to revenue growth and profitability will depend on implementation timelines and subsequent customer demand.
Likely Trend of VEEV Stock Following the News
Following the announcement, shares of VEEV traded flat in yesterday’s trading. Year to date, shares of the company have gained 35.1% compared with the industry’s 19.1% growth. However, the S&P 500 has risen 13.8% in the same timeframe.
The expanded partnership with IQVIA is likely to support VEEV’s long-term growth by strengthening the adoption of its clinical applications across a major clinical research organization. Making Veeva’s solutions standard applications for IQVIA’s clinical development studies could increase product visibility, deepen its presence in the clinical research ecosystem and create opportunities to reach more biopharmaceutical customers. The collaboration also strengthens the value proposition of Veeva’s clinical technology portfolio by enabling deeper integration and more efficient workflows.
VEEV currently has a market capitalization of $47.9 billion.
Image Source: Zacks Investment Research
More on Veeva’s Clinical Operations Software Suite
VEEV is expanding its role in clinical research by being selected as the enterprise-standard solution for IQVIA’s clinical development studies. The agreement covers Veeva Clinical Trial Management System (CTMS), electronic Trial Master File (eTMF), Study Startup and Site Connect, extending the companies’ previously announced EDC partnership. These applications are designed to support key stages of clinical trials, from study planning and site activation to trial management and documentation.
Their adoption across IQVIA’s clinical development activities is expected to support more connected workflows, improve operational efficiency and strengthen coordination among clinical research stakeholders. The collaboration also builds on the companies’ complementary capabilities, with IQVIA emphasizing that customers will retain flexibility in selecting electronic data capture, randomization and trial supply management and electronic clinical outcome assessment technologies.
Expanded Collaboration Could Strengthen Veeva’s Market Position
The partnership could provide Veeva with a broader channel to market its clinical applications to biopharmaceutical companies that rely on IQVIA for clinical research services. IQVIA’s selection of multiple Veeva applications as enterprise standards may also strengthen customer confidence in the company’s technology and encourage sponsors to consider adopting a wider range of its solutions.
In addition, IQVIA will make Veeva’s full clinical solution portfolio available to sponsors seeking an integrated technology stack, creating a potential avenue for cross-selling. The collaboration is aimed at improving trial efficiency, strengthening clinical site engagement and enabling better-informed decisions through more connected technology workflows.
Over the longer term, these factors could support broader product adoption and recurring revenue growth for Veeva.
However, the companies have not disclosed financial terms or a deployment timeline, making the eventual revenue contribution difficult to quantify at this stage.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global healthcare CRM market size was valued at $21.5 billion in 2025 and is projected to grow from $23.3 billion in 2026 to $35.7 billion by 2033, at a CAGR of 6.2% from 2026 to 2033.
The rising demand for structured data and automation in healthcare organizations is expected to drive market growth.
Other News
VEEV continues to strengthen its position in the life sciences software market as the Veeva DQS platform expands reach across clinical trials. The company said the solution now supports data cleaning across more than 1,000 studies involving over 1 million subjects, highlighting growing adoption of its clinical data management capabilities.
The expanding scale of Veeva DQS is encouraging as biopharma companies increasingly prioritize efficient data management amid rising clinical trial complexity.
VEEV’s Zacks Rank & Key Picks
Currently, VEEV has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Merit Medical Systems, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.